Concise review: Managing genotoxicity in the therapeutic modification of stem cells

Stem Cells

Volumn 29, Issue 10, 2011, Pages 1479-1484

  Baum, Christopher ^a   Modlich, Ute ^a   Göhring, Gudrun ^a   Schlegelberger, Brigitte ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Adult hematopoietic stem cells; Gene delivery systems; Gene therapy; Pluripotent stem cells

Indexed keywords

CANCER GROWTH; CELL EXPANSION; GENE MUTATION; GENE THERAPY; GENETIC STABILITY; GENOME; GENOTOXICITY; GROWTH RATE; HOMEOSTASIS; HUMAN; INCIDENCE; LEUKEMIA; MUTAGENESIS; ONCOGENE; PLURIPOTENT STEM CELL; REVIEW; STEM CELL TRANSPLANTATION; TARGET CELL;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; CLONE CELLS; DNA DAMAGE; DNA-BINDING PROTEINS; GENE THERAPY; GENETIC VECTORS; GENOMIC INSTABILITY; HEMATOPOIETIC STEM CELLS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; LIM DOMAIN PROTEINS; MUTAGENESIS, INSERTIONAL; MUTATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENES; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; TRANSGENES;

EID: 80053228856     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.716     Document Type: Review

References (67)

1. Boitano AE, Wang J, Romeo R et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science 2010;329:1345-1348.
2. Chou S, Chu P, Hwang W et al. Expansion of human cord blood hematopoietic stem cells for transplantation. Cell Stem Cell 2010;7:427-428.
3. Cavazzana-Calvo M, Fischer A, Bushman FD et al. Is normal hematopoiesis maintained solely by long-term multipotent stem cells?Blood 2011;117:4420-4424.
4. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663-676. (Pubitemid 44233629)
5. Hanna JH, Saha K, Jaenisch R. Pluripotency and cellular reprogramming: Facts, hypotheses, unresolved issues. Cell 2010;143:508-525.
6. Li Z, Dullmann J, Schiedlmeier B et al. Murine leukemia induced by retroviral gene marking. Science 2002;296:497. (Pubitemid 34408663)
7. Modlich U, Kustikova OS, Schmidt M et al. Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. Blood 2005;105:4235-4246. (Pubitemid 40720768)
8. Hacein-Bey-Abina S, Von Kalle C, Schmidt M et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003;302:415-419. (Pubitemid 37296260)
9. Howe SJ, Mansour MR, Schwarzwaelder K et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008;118:3143-3150.
10. Hacein-Bey-Abina S, Garrigue A, Wang GP et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008;118:3132-3142.
11. Stein S, Ott MG, Schultze-Strasser S et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010;16:198-204.
12. Handel EM, Cathomen T. Zinc-finger nuclease based genome surgery: It's all about specificity. Curr Gene Ther 2011;11:28-37.
13. Zhang XB, Beard BC, Trobridge GD et al. High incidence of leukemia in large animals after stem cell gene therapy with a HOXB4-expressing retroviral vector. J Clin Invest 2008;118:1502-1510. (Pubitemid 351500443)
14. Baker DE, Harrison NJ, Maltby E et al. Adaptation to culture of human embryonic stem cells and oncogenesis in vivo. Nat Biotechnol 2007;25:207-215. (Pubitemid 46227120)
15. Catalina P, Montes R, Ligero G et al. Human ESCs predisposition to karyotypic instability: Is a matter of culture adaptation or differential vulnerability among hESC lines due to inherent properties?Mol Cancer 2008;7:76.
16. Sellers S, Gomes TJ, Larochelle A et al. Ex vivo expansion of retrovirally transduced primate CD34+ cells results in overrepresentation of clones with MDS1/EVI1 insertion sites in the myeloid lineage after transplantation. Mol Ther 2010;18:1633-1639.
17. Maetzig T, Brugman MH, Bartels S et al. Polyclonal fluctuation of lentiviral vector-transduced and expanded murine hematopoietic stem cells. Blood 2011;117:3053-3064.
18. Hayward WS, Neel BG, Astrin SM. Activation of a cellular onc gene by promoter insertion in ALV-induced lymphoid leukosis. Nature 1981;290:475-480. (Pubitemid 11159077)
19. Kool J, Berns A. High-throughput insertional mutagenesis screens in mice to identify oncogenic networks. Nat Rev Cancer 2009;9:389-399.
20. Cattoglio C, Pellin D, Rizzi E et al. High-definition mapping of retroviral integration sites identifies active regulatory elements in human multipotent hematopoietic progenitors. Blood 2010;116:5507-5517.
21. Biffi A, Bartolomae CC, Cesana D et al. Lentiviral-vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. Blood 2011;117:5332-5339.
22. Kustikova O, Fehse B, Modlich U et al. Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science 2005;308:1171-1174. (Pubitemid 40696434)
23. Modlich U, Schambach A, Brugman MH et al. Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16. Leukemia 2008;22:1519-1528.
24. Goyama S, Yamamoto G, Shimabe M et al. Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells. Cell Stem Cell 2008;3:207-220.
25. Aguilo F, Avagyan S, Labar AS et al. Prdm16 is a physiological regulator of hematopoietic stem cells. Blood 2011;117:5057-5066.
26. Aiuti A, Cattaneo F, Galimberti S et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009;360:447-458.
27. Seggewiss R, Pittaluga S, Adler RL et al. Acute myeloid leukemia is associated with retroviral gene transfer to hematopoietic progenitor cells in a rhesus macaque. Blood 2006;107:3865-3867. (Pubitemid 43726789)
28. Ott MG, Schmidt M, Schwarzwaelder K et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 Or SETBP1. Nat Med 2006;12:401-409.
29. Cavazzana-Calvo M, Payen E, Negre O et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 2010;467:318-322.
30. Kustikova OS, Schiedlmeier B, Brugman MH et al. Cell-intrinsic and vector-related properties cooperate to determine the incidence and consequences of insertional mutagenesis. Mol Ther 2009;17:1537-1547.
31. Wang GP, Berry CC, Malani N et al. Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial. Blood 2010;115:4356-4366.
32. Newrzela S, Cornils K, Li Z et al. Resistance of mature T cells to oncogene transformation. Blood 2008;112:2278-2286.
33. Curtis DJ, McCormack MP. The molecular basis of Lmo2-induced T-cell acute lymphoblastic leukemia. Clin Cancer Res 2010;16:5618-5623.
34. Wiemels JL, Ford AM, van Wering ER et al. Protracted and variable latency of acute lymphoblastic leukemia after TEL-AML1 gene fusion in utero. Blood 1999;94:1057-1062. (Pubitemid 29361838)
35. Dunbar CE, Larochelle A. Gene therapy activates EVI1, destabilizes chromosomes. Nat Med 2010;16:163-165.
36. Anderson K, Lutz C, van Delft FW et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011;469:356-361.
37. Warlich E, Kuehle J, Cantz T et al. Lentiviral vector design and imaging approaches to visualize the early stages of cellular reprogramming. Mol Ther 2011;19:782-789.
38. Cowan CA, Klimanskaya I, McMahon J et al. Derivation of embryonic stem-cell lines from human blastocysts. N Engl J Med 2004;350:1353-1356. (Pubitemid 38375373)
39. Liu X, Wu H, Loring J et al. Trisomy eight in ES cells is a common potential problem in gene targeting and interferes with germ line transmission. Dev Dyn 1997;209:85-91. (Pubitemid 27188341)
40. Louis SF, Vermolen BJ, Garini Y et al. c-Myc induces chromosomal rearrangements through telomere and chromosome remodeling in the interphase nucleus. Proc Natl Acad Sci USA 2005;102:9613-9618. (Pubitemid 40981729)
41. Woltjen K, Michael IP, Mohseni P et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 2009;458:766-770.
42. Nakagawa M, Takizawa N, Narita M et al. Promotion of direct reprogramming by transformation-deficient Myc. Proc Natl Acad Sci USA 2010;107:14152-14157.
43. Pera MF. Stem cells: The dark side of induced pluripotency. Nature 2011;471:46-47.
44. Hong H, Takahashi K, Ichisaka T et al. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 2009;460:1132-1135.
45. Raya A, Rodriguez-Piza I, Guenechea G et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature 2009;460:53-59.
46. Laurent LC, Ulitsky I, Slavin I et al. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell 2011;8:106-118.
47. Narva E, Autio R, Rahkonen N et al. High-resolution DNA analysis of human embryonic stem cell lines reveals culture-induced copy number changes and loss of heterozygosity. Nat Biotechnol 2010;28:371-377.
48. Hussein SM, Batada NN, Vuoristo S et al. Copy number variation and selection during reprogramming to pluripotency. Nature 2011;471:58-62.
49. Sommer CA, Sommer AG, Longmire TA et al. Excision of reprogramming transgenes improves the differentiation potential of iPS cells generated with a single excisable vector. Stem Cells 2010;28:64-74.
50. Chang CW, Lai YS, Pawlik KM et al. Polycistronic lentiviral vector for "hit and run" reprogramming of adult skin fibroblasts to induced pluripotent stem cells. Stem Cells 2009;27:1042-1049.
51. Voelkel C, Galla M, Maetzig T et al. Protein transduction from retroviral Gag precursors. Proc Natl Acad Sci USA 2010;107:7805-7810.
52. Okita K, Nakagawa M, Hyenjong H et al. Generation of mouse induced pluripotent stem cells without viral vectors. Science 2008;322:949-953.
53. Warren L, Manos PD, Ahfeldt T et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010;7:618-630.
54. Anokye-Danso F, Trivedi CM, Juhr D et al. Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell 2011;8:376-388.
55. Thier M, Munst B, Edenhofer F. Exploring refined conditions for reprogramming cells by recombinant Oct4 protein. Int J Dev Biol 2010;54:1713-1721.
56. Gabriel R, Eckenberg R, Paruzynski A et al. Comprehensive genomic access to vector integration in clinical gene therapy. Nat Med 2009;15:1431-1436.
57. Brady T, Roth SL, Malani N et al. A method to sequence and quantify DNA integration for monitoring outcome in gene therapy. Nucleic Acids Res 2011;39:e72.
58. Bosticardo M, Ghosh A, Du Y et al. Self-inactivating retroviral vector-mediated gene transfer induces oncogene activation and immortalization of primary murine bone marrow cells. Mol Ther 2009;17:1910-1918.
59. Li CL, Xiong D, Stamatoyannopoulos G et al. Genomic and functional assays demonstrate reduced gammaretroviral vector genotoxicity associated with use of the cHS4 chromatin insulator. Mol Ther 2009;17:716-724.
60. Knight S, Bokhoven M, Collins M et al. Effect of the internal promoter on insertional gene activation by lentiviral vectors with an intact HIV long terminal repeat. J Virol 2010;84:4856-4859.
61. Modlich U, Navarro S, Zychlinski D et al. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther 2009;17:1919-1928.
62. Montini E, Cesana D, Schmidt M et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest 2009;119:964-975.
63. Ryu BY, Evans-Galea MV, Gray JT et al. An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene activation. Blood 2008;111:1866-1875. (Pubitemid 351451495)
64. Trobridge GD, Kiem HP. Large animal models of hematopoietic stem cell gene therapy. Gene Ther 2010;17:939-948.
65. Laufs S, Gentner B, Nagy KZ et al. Retroviral vector integration occurs in preferred genomic targets of human bone marrow-repopulating cells. Blood 2003;101:2191-2198. (Pubitemid 36302057)
66. Bauer G, Dao MA, Case SS et al. In vivo biosafety model to assess the risk of adverse events from retroviral and lentiviral vectors. Mol Ther 2008;16:1308-1315. (Pubitemid 351866063)
67. Wunderlich M, Chou FS, Link KA et al. AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF And IL-3 Leukemia 2010;24:1785-1788.